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The ﬁrst successful human-to-human blood transfusion was
performed in the 1820s by British obstetrician James
Blundell to treat a woman with post-partum hemorrhage
(1). Although there had been more than 200 years of
research into blood, relatively little was known at that time,
and the identiﬁcation of blood groups by Landsteiner was
still several decades away. Animal-to-human blood trans-
fusion had been attempted, but the failure of these experi-
ments suspended any signiﬁcant progress in the ﬁeld for
almost 150 years. In 1816, John Henry Leacock established
the importance of species compatibility for successful
transfusion (2). Blundell followed Leacock’s work, and when
faced with a patient who was exsanguinating, he extracted
blood from the patient’s husband and transfused it, saving
the woman’s life.See page 1289Since that ﬁrst success in transfusion medicine, much
progress has been made, particularly in the areas of blood
compatibility and transfusion safety as it relates to the
transmissibility of infectious agents. Risks associated with
transfusion and the relative frequency of these events are
shown in Figure 1. There has also been signiﬁcant progress
in determining the role of transfusion in children and adults
with critical illness (3,4), as well as in patients with acute
upper gastrointestinal hemorrhage (5). Randomized trials
in these clinical settings have demonstrated that restrictive
use of blood transfusionddeﬁned in the trials as main-
taining a hemoglobin value of 7 g/dldis associated with
either similar or better outcomes compared with liberal
transfusion, deﬁned as maintaining a hemoglobin value of*Editorials published in the Journal of the American College of Cardiology reﬂect the
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paper to disclose.9 g/dl or higher. It is becoming clear that in many scenarios,
a restrictive transfusion strategy is preferred. The one
exception is in anemic patients with ischemic heart disease,
including acute coronary syndrome (ACS), for which
guidelines indicate that the role of blood transfusion is not
known (6). This is due to the lack of adequately powered
randomized trial data supporting one strategy over the other.
Observational studies examining the association between
red blood cell transfusion and outcomes in patients with
ACS have shown either no beneﬁt or an increased risk for
mortality with transfusion above a nadir hematocrit of 24%
(hemoglobin of 8 g/dl) (7,8) or a baseline hematocrit of 33%
(9). In this issue of the Journal, Silvain et al. (10) provide
some potential mechanistic insights into these ﬁndings. In a
cross-sectional, observational, prospective study, they exam-
ined the association between red blood cell transfusion and
measures of platelet reactivity using multiple assays, includ-
ing vasodilator-stimulated phosphoprotein–1, thrombin
receptor–activated peptide–1, and adenosine diphosphate–
induced light transmission aggregometry. The population
studied was diverse, including patients with ACS, patients
with congestive heart failure, those receiving dual-antiplatelet
therapy, as well as patients not receiving antiplatelet therapy.
Silvain et al. found that transfusion was associated with a
modest but signiﬁcant increase in measures of platelet reac-
tivity, which occurred in the presence of no change in
inﬂammatory biomarkers. The increase in platelet reactivity
was most robust in patients with ACS previously taking
P2Y12 inhibitors, and there did not seem to be a strong
relationship between the duration of red blood cell storage
and the effect of platelet reactivity.
These new ﬁndings should be considered in the context of
the known role of platelet activation and aggregation in the
pathophysiology of ACS and ACS-related sequelae (11).
Increased platelet reactivity has been described as a risk
factor for adverse outcomes in patients with ACS and those
undergoing percutaneous coronary intervention (12). The
increased platelet reactivity induced by blood transfusion
could explain the association between transfusion and the
increased risk for recurrent myocardial infarction (MI) seen
in the observational studies (7). In light of these mechanistic
data, do the reported results further the case for withholding
transfusion in patients with ACS?
To answer this question, it is important to review what is
known about anemia, transfusion, and outcomes in the ACS
population. As mentioned previously, the observational data
show an association between transfusion above a hemoglo-
bin level of 8 g/dl and either no effect on mortality or an
increased risk for mortality. In contrast, anemia is an inde-
pendent predictor of mortality in patients with ACS (13).
Because ACS is a state in which the myocardium is deprived
of oxygen, anemia could further exacerbate myocardial
ischemia in patients with coronary stenoses (14). Increasing
hemoglobin through transfusion should increase oxygen
delivery and mitigate myocardial ischemia, but experimental
studies have indicated no increase in tissue oxygenation with
Figure 1 Adverse Effects of RBC Transfusion Contrasted With Other Risks
Risk is depicted on a logarithmic scale. Shaded bars represent the risk per red blood cell (RBC) unit transfused, and unshaded bars represent the risk for fatality per person per
year for various life events. HBV ¼ hepatitis B virus; HCV ¼ hepatitis C virus; RBC ¼ red blood cell; TACO ¼ transfusion-associated circulatory overload; TRALI ¼ transfusion-
related acute lung injury. Reprinted, with permission, from Carson et al. (6).
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1298transfusion (15). This may be due to chemical changes in red
cells that occur during storage (the so-called storage lesion),
such as depletion of 2,3-diphosphoglycerate and nitric
oxide, that diminish the ability of transfusion to deliver
oxygen (16). The study of Silvain et al. (10) adds another
potential mechanism by which transfusion may be harmful;
however, some limitations of their study should be noted.
First, the effect of transfusion on platelet function may be
transient, and platelet function may return to normal after a
certain period of time. Thus, post-transfusion platelet func-
tion may not necessarily affect 30-day or longer-term out-
comes. Second, all of the patients in the study of Silvain et al.
(10) were anemic, and there may be an interaction among the
degree of anemia, the robustness of hemoglobin correction
with transfusion, and platelet function. In other words, there
may be a gradient of the effect on platelet function across
patients with ACS on the basis of their anemia that was not
explored in the study. Third, in a randomized trial comparing
transfusion strategies among patients with acute upper
gastrointestinal bleeding, patients assigned to liberal trans-
fusion had a higher rate of recurrent hemorrhage (5), sug-
gesting that other effects of transfusion on hemostatic
mechanisms may offset increases in platelet reactivity.
Finally, long-term clinical outcomes were not measured.
It is also important to review the limitations of the pub-
lished data on transfusion and clinical outcomes in pa-
tients with ACS. As mentioned previously, the data arederived predominantly from observational analyses, and
observational assessment of a therapy for which the indica-
tion for the treatment may itself be associated with adverse
outcomes leads to “confounding by indication” that is un-
likely to be overcome regardless of the statistical technique
used (17). Only 2 small, randomized trials of red blood cell
transfusion in patients with acute MI have been published
(18,19). The CRIT Randomized Pilot Trial (Conservative
Versus Liberal Red Cell Transfusion in Acute Myocardial
Infarction) assigned 45 patients with MI and hematocrit
30% within 72 h of admission to a liberal versus a con-
servative transfusion strategy: maintaining hematocrit of
30% to 33% versus 24% to 27% (18). Although the trial was
not powered for a speciﬁc endpoint, patients assigned to
liberal transfusion had a signiﬁcantly higher rate of the
composite endpoint of in-hospital death, recurrent MI, or
congestive heart failure compared with patients assigned
to the restrictive arm (38% vs. 13%, p ¼ 0.046). This is
countered by the Myocardial Ischemia and Transfusion
trial, which randomized 110 patients with ACS or stable
angina undergoing percutaneous coronary intervention with
hemoglobin values <10 g/dl to either a liberal (maintaining
hemoglobin 10 g/dl) or conservative (transfusion for symp-
toms or hemoglobin <8 g/dl) transfusion strategy (19). In the
liberal transfusion group, there was a statistically insigniﬁcant
lower rate of 30-day death, MI, or unscheduled revasculari-
zation, which was the primary endpoint, and a signiﬁcantly
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1299lower rate of 30-day mortality. In addition, a subgroup analysis
of the Transfusion Requirement in Critical Care trial also
showeda trend toward reduced30-daymortality amongpatients
with cardiovascular disease assigned to the liberal transfusion
strategy (20). These conﬂicting clinical trial data from studies
using different populations, designs, and endpoints explain
the inability of the guidelines to make any recommendation
on the role of transfusion in this high-risk patient population.
They also underscore the urgent need for a deﬁnitive
randomized trial of transfusion strategies in patients with
ACS. Large registries indicate that up to 10% of patients
with ACS receive blood transfusions during their hospital-
izations, translating into about 130,000 patients with ACS
receiving transfusions annually. Given the lack of data in
this population, it is impossible to know how many of these
transfusions are inappropriate. To date, there remains
equipoise in the ﬁeld, with no strong evidence for or against
red blood cell transfusion in patients with ACS.
In this context, the biases of physicians caring for patients
with ACS run deep. A survey of Canadian physicians per-
formed before the landmark Transfusion Requirement in
Critical Care trial of transfusion strategies in critically ill pa-
tients (3) showed that the majority believed that the appro-
priate transfusion “trigger” for patients with acute ischemic
heart disease was a hemoglobin level of 10 g/dl (hematocrit
of 30%) (21). That is, such patients should receive transfusions
if their hemoglobin levels fall below 10 g/dl. In contrast, Eu-
ropean practice guidelines for patients with unstable angina
or non–ST-segment elevation MI published more recently
have recommended that transfusion be withheld unless a pa-
tient is symptomatic from anemia or the hemoglobin level is
less than 8 g/dl (22). Ostensibly, these recommendations are
based on the published observational data, which have the
limitations outlined earlier. This disparity crystallizes the de-
sign of a deﬁnitive randomized trial of transfusion strategies in
ACS. Such a trial should be adequately powered to determine
whether maintaining a hemoglobin level of 8 or 10 g/dl re-
ducesmajor adverse cardiac events in patients withACS.Given
the impact of “bleeding-avoidance strategies” on decreasing
bleeding and transfusion rates after percutaneous coronary
intervention (23), the trial will necessarily enroll patients with
multiple comorbidities, including frailty, who are likely much
sicker and at higher risk for adverse outcomes than the pati-
ents enrolled in prior ACS trials. Although such a study may
be challenging to undertake, pilot studies have shown that
a transfusion strategy trial is feasible in this setting (18,19).
It has been almost 200 years since the ﬁrst landmark event
in transfusion medicine. The time for determining the role
of blood transfusion in patients with ACSdpatients who are
at the highest risk for bleeding and stand to beneﬁt the most
from strategies that mitigate cardiac ischemiadis now.
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